Skip to search formSkip to main contentSkip to account menu

cabazitaxel

Known as: 1-hydroxy-7beta,10beta-dimethoxy-9-oxo-5beta,20-epoxytax-11-ene-2alpha,4,13alpha-triyl 4-acetate 2-benzoate 13-[(2R,3S)-3-{[(tertbutoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoate], 4-acetoxy-13-((3-((tert-butoxycarbonyl)amino)-2-hydroxy-3-phenylpropanoyl)oxy)-1-hydroxy-7,10-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate, Cabazitaxelum 
A semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity. Cabazitaxel binds to and stabilizes… 
National Institutes of Health

Related topics

Related topics

10 relations
1.5 ML cabazitaxel 40 MG/ML Injection1.5 ML cabazitaxel 40 MG/ML Injection [Jevtana]ApoptosisMicrotubule Process

Narrower (3)

JevtanaTXD 258XRP6258

Broader (1)

Taxoids

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2020
Highly Cited
2020
Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States.
Review
2018
Review
2018
Metastatic prostate cancer remains incurable, why?
Highly Cited
2017
Highly Cited
2017
Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.
Purpose Cabazitaxel 25 mg/m2 (C25) significantly improved overall survival (OS) versus mitoxantrone ( P < .001) in postdocetaxel… 
Review
2017
Review
2017
Role of chemotherapy in prostate cancer
Chemotherapy in prostate cancer (PCa) has undergone dramatic landscape changes. While earlier studies utilized varying… 
Highly Cited
2015
Highly Cited
2015
Serum exosomal P-glycoprotein is a potential marker to diagnose docetaxel resistance and select a taxoid for patients with prostate cancer.
Highly Cited
2015
Highly Cited
2015
High subcutaneous adipose tissue predicts the prognosis in metastatic castration-resistant prostate cancer patients in post chemotherapy setting.
Highly Cited
2014
Highly Cited
2014
Self-assembled micelles of novel amphiphilic copolymer cholesterol-coupled F68 containing cabazitaxel as a drug delivery system
Despite being one of the most promising amphiphilic block copolymers, use of Pluronic F68 in drug delivery is limited due to its… 
Highly Cited
2013
Highly Cited
2013
Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
Review
2011
Review
2011
Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
Until recently, patients with castration-resistant prostate cancer (CRPC) had limited therapeutic options once they became… 
Highly Cited
2011
Highly Cited
2011
TROPIC: Phase III trial of cabazitaxel for the treatment of metastatic castration-resistant prostate cancer.
For patients with metastatic castration-resistant prostate cancer (mCRPC), the current standard of care is chemotherapy involving… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)